T002 HHSN2610002 Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers - Task Order 2015 E-02 - Evaluation of Agents/Protocols that Inhibity the Two Major Pathways Involved in Human Urinary Bladder Cancer [PI3K, EGFR] and Protocols to Reduce their Toxicity

Grant

Date/time Interval

  • September 15, 2015 - September 16, 2021
  • Total Award Amount

  • 679103.00
  • Direct Costs

  • 461975.00
  • Sponsor Award Id

  • HHSN261201500036I-HHSN2610002
  • Contributor

  • Grubbs Ph.D., Clinton   Principal Investigator  
  • Juliana, M   Investigator